Journal of Peking University(Health Sciences) >
Strategy of reoperation for pheochromocytoma and paraganglioma
Received date: 2021-03-22
Online published: 2021-08-25
Objective: To explore the surgical strategy and experience of reoperation for pheochromocytoma and paraganglioma which is very challenging. Methods: The clinical data of 7 patients with pheochromocytoma and paraganglioma who underwent reoperation in Department of Urology, Peking University Third Hospital from August 2016 to February 2021 were analyzed retrospectively. There were 4 males and 3 females, with an average age of (44.1±11.5) years (28-60 years), 6 cases on the right side and 1 case on the left side. The causes of the operations included: (1) 2 cases of tumor recurrence after resection; (2) The primary operations failed to completely remove the tumors in 3 cases, because the tumors were large and closely related to blood vessels. (3) Pheochromocytoma and paraganglioma wasn’t diagnosed before primary operation, therefore, drug preparation wasn’t prepared. Two cases were interrupted by severe blood pressure fluctuations during the primary operations. Imaging evaluation, catecholamine biochemical examination and adequate adrenergic α receptor blockers were administrated in all the cases. The surgical approaches included open transperitoneal surgery in 4 cases, robot-assisted laparoscopy in 1 case and retroperitoneal laparoscopy in 2 cases. The innovative techniques included mobilization of the liver, inferior vena cava transection and anastomosis, and transection of left renal vein. Results: The average tumor size was (8.0±3.2) cm (3.6-13.9 cm). The median interval between the reoperation and the primary operation was 9 months (IQR: 6,19 months). The median operation time was 407 min (IQR: 114, 430 min) and the median blood loss was 1 500 mL (IQR: 20, 3 800 mL). Operations of 5 cases were performed successfully, and 1 case failed only by exploration during the operation. One case died perioperatively. There were 5 cases of intraoperative blood transfusion, the median transfusion volume of red blood cells was 800 mL (IQR: 0, 2 000 mL). One case experienced postoperative lymphorrhagia, and recovered after conservative treatment. The renal function was normal in 2 cases after resection and anastomosis of inferior vena cava or transection of left renal vein. The average postoperative hospital stay was (7.2±3.3) d (4-13 d). The median follow-up time of 6 patients was 33.5 months (IQR: 4.8, 48.0 months). The case who failed in the reoperation still survived with tumor and there was no recurrence in the rest of the patients. Conclusion: The reoperation of pheochromocytoma and paraganglioma, which can not be resected in the primary operation or recurred postoperatively, is difficult with high risk of hemorrhage, and there is a risk of failure and perioperative death. Different surgical approaches and strategies need to be adopted based on the different situation.
Key words: Pheochromocytoma; Paraganglioma; Reoperation; Recurrence
Lei LIU , Yan-chun QIN , Guo-liang WANG , Shu-dong ZHANG , Xiao-fei HOU , Lu-lin MA . Strategy of reoperation for pheochromocytoma and paraganglioma[J]. Journal of Peking University(Health Sciences), 2021 , 53(4) : 793 -797 . DOI: 10.19723/j.issn.1671-167X.2021.04.029
| [1] | Hamidi O, Young WF Jr., Iñiguez-Ariza NM, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years [J]. J Clin Endocrinol Metab, 2017, 102(9):3296-3305. |
| [2] | Davison AS, Jones DM, Ruthven S, et al. Clinical evaluation and treatment of phaeochromocytoma [J]. Ann Clin Biochem, 2018, 55(1):34-48. |
| [3] | Hamidi O, Young WF Jr., Gruber L, et al. Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A syste-matic review and meta-analysis [J]. Clin Endocrinol (Oxf), 2017, 87(5):440-450. |
| [4] | Lam AK. Update on adrenal tumours in 2017 World Health Orga-nization (WHO) of endocrine tumours [J]. Endocr Pathol, 2017, 28(3):213-227. |
| [5] | Wilhelm SM, Prinz RA, Barbu AM, et al. Analysis of large versus small pheochromocytomas: Operative approaches and patient outcomes [J]. Surgery, 2006, 140(4):553-560. |
| [6] | Amar L, Servais A, Gimenez-Roqueplo AP, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma [J]. J Clin Endocrinol Metab, 2005, 90(4):2110-2116. |
| [7] | Edstrom Elder E, Hjelm Skog AL, Hoog A, et al. The management of benign and malignant pheochromocytoma and abdominal paraganglioma [J]. Eur J Surg Oncol, 2003, 29(3):278-283. |
| [8] | Sbardella E, Grossman AB. Pheochromocytoma: An approach to diagnosis [J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(2):101346. |
| [9] | Sonbare DJ, Abraham DT, Rajaratnam S, et al. Re-operative surgery for pheochromocytoma-paraganglioma: Analysis of 13 cases from a single institution [J]. Indian J Surg, 2018, 80(2):123-127. |
| [10] | Aggeli C, Nixon AM, Parianos C, et al. Surgery for pheochromocytoma: A 20-year experience of a single institution [J]. Hormones (Athens), 2017, 16(4):388-395. |
| [11] | Hassan T, de la Taille A, Ingels A. Right robot-assisted partial adrenalectomy for pheochromocytoma with video [J]. J Visc Surg, 2020, 157(3):259-260. |
| [12] | Soejima Y, Yoshizumi T, Ikegami T, et al. Surgical resection of giant pheochromocytomas arising behind the retrohepatic inferior vena cava [J]. Anticancer Res, 2017, 37(1):277-280. |
/
| 〈 |
|
〉 |